Trial reportBlood2017
Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
Open access · bronzeAbstract readClinical Trial
In one paragraph
Trial report in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 153 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
153citing papers in PubMed, 2 pooled it
31.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
153 citing papers in PubMed, 2 syntheses or guidelines pooled it, 302 citations in OpenAlex.
- A meta-analysis of diagnostic challenges in Ph-like ALL at baseline: early detection strategies for personalized therapeutic interventions.International journal of hematology · 2025Pooled it
- The role of chemokines and interleukins in acute lymphoblastic leukemia: a systematic review.Journal of applied biomedicine · 2024Pooled it
- Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001.Blood advances · 2022Trial
- Trial
- Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study.The Lancet. Haematology · 2021Trial
- At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial.British journal of haematology · 2020Trial
- Trial
- Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic Leukemia identifies subtype-specific cytokine and metabolic signatures.Scientific reports · 2019Trial
- Trial
- High-risk features in adult patients with B-cell acute lymphoblastic leukemia: redefining risk in the era of targeted immunotherapy.Blood research · 2026Review
- RNA Sequencing Technologies in Acute Lymphoblastic Leukemia: A Comparative Technical Review.Current issues in molecular biology · 2026Review
- [Clinical features ofZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- Advances in the diagnosis and classification of B-ALL: comparative insights from updated guidelines.Blood advances · 2026Article
- Article
- Identification of the Philadelphia-like subgroup in Turkish pediatric patients with acute lymphoblastic leukemia.Annals of hematology · 2026Article
- From the bench of molecular understanding to the bedside of optimal therapy forEJC paediatric oncology · 2025Article
- The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.Bone marrow transplantation · 2025Article
- A Decade of Transformation in the Management of Childhood Acute Lymphoblastic Leukemia: From Conventional Chemotherapy to Precision Medicine.Pediatric reports · 2025Review
- Review
- Review
93 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
35 authors at 17 institutions in 1 country.
Shalini C ReshmiInstitute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH.
Richard C HarveyUniversity of New Mexico Cancer Center, Albuquerque, NM.ORCID 0000-0002-4904-9767
Kathryn G RobertsDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
Eileen StonerockInstitute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH.
Amy SmithComprehensive Cancer Center, The Ohio State University College of Medicine, Columbus, OH.
Heather JenkinsInstitute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH.
I-Ming ChenUniversity of New Mexico Cancer Center, Albuquerque, NM.
Marc ValentineDepartment of Cytogenetics and.
Yu LiuDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN.
Yongjin LiDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN.
Ying ShaoDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
John EastonDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN.
Debbie Payne-TurnerDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
Zhaohui GuDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
Thai Hoa TranDepartment of Pediatrics, UCSF Benioff Children's Hospital and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.
Jonathan V NguyenDepartment of Pediatrics, UCSF Benioff Children's Hospital and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.
Meenakshi DevidasDepartment of Biostatistics, University of Florida, Gainesville, FL.
Yunfeng DaiDepartment of Biostatistics, University of Florida, Gainesville, FL.
Nyla A HeeremaDepartment of Pathology, The Ohio State University College of Medicine, Columbus, OH.
Andrew J CarrollDepartment of Genetics, University of Alabama at Birmingham, Birmingham, AL.
Elizabeth A RaetzDepartment of Pediatrics, University of Utah, Salt Lake City, UT.
Michael J BorowitzDepartment of Pathology, Johns Hopkins University, Baltimore, MD.
Brent L WoodSeattle Children's Hospital, Seattle, WA.
Anne L AngiolilloChildren's National Medical Center, Washington, DC.
Michael J BurkeDepartment of Pediatrics, Medical College of Wisconsin, Milwaukee, WI.
Wanda L SalzerUS Army Medical Research and Materiel Command, Fort Detrick, MD.
Patrick A Zweidler-McKayDepartment of Pediatrics, MD Anderson Cancer Center, Houston, TX.
Karen R RabinDepartment of Pediatrics, Baylor College of Medicine, Houston, TX.
William L CarrollPerlmutter Cancer Center, NYU Langone Medical Center, New York, NY.
Jinghui ZhangDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN.
Mignon L LohDepartment of Pediatrics, UCSF Benioff Children's Hospital and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.
Charles G MullighanDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
Cheryl L WillmanUniversity of New Mexico Cancer Center, Albuquerque, NM.
Julie M Gastier-FosterInstitute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH.
Stephen P HungerDepartment of Pediatrics, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
St. Jude Children's Research Hospital · USNationwide Children's Hospital · USUniversity of California, San Francisco · USUniversity of New Mexico · USThe Ohio State University · USUniversity of Florida · USBaylor College of Medicine · USChildren's Hospital of Philadelphia · USChildren's National · USJohns Hopkins University · USMedical College of Wisconsin · USNYU Langone Health · USSeattle Children's Hospital · USThe University of Texas MD Anderson Cancer Center · USUnited States Army Medical Research and Development Command · USUniversity of Alabama at Birmingham · USUniversity of Utah · US
Funding
NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6MViral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9MCOG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3MCPML - Project 3: Genome-wide Studies of Adverse EffectsP50GM115279 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI LOH, MIGNON LEE-CHEUN, RELLING, MARY V · 2015 to 2019
$15.1MNCI NIH HHS P30 CA016058NCI NIH HHS P30 CA021765NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NIGMS NIH HHS P50 GM115279
Abstract
Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a high-risk subtype characterized by genomic alterations that activate cytokine receptor and kinase signaling. We examined the frequency and spectrum of targetable genetic lesions in a retrospective cohort of 1389 consecutively diagnosed patients with childhood B-lineage ALL with high-risk clinical features and/or elevated minimal residual disease at the end of remission induction therapy. The Ph-like gene expression profile was identified in 341 of 1389 patients, 57 of whom were excluded from additional analyses because of the presence of
Indexed as
Gene FusionChildFemaleFusion Proteins, bcr-ablGene Expression Regulation, LeukemicHumansInterleukin-7 Receptor alpha SubunitJanus Kinase 2MaleMutationPhiladelphia ChromosomePrecursor B-Cell Lymphoblastic Leukemia-LymphomaProtein KinasesReceptors, CytokineRetrospective StudiesTranscriptomeCRLF2 protein, humanFusion Proteins, bcr-ablIL7R protein, humanInterleukin-7 Receptor alpha SubunitJAK2 protein, humanJanus Kinase 2Protein KinasesReceptors, Cytokine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.